Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The core study looked at the effect of Zoledronic Acid given once as an intravenous (i.v.) infusion compared to 60 days of oral Risedronate in patients with Paget's disease of bone. The effect was demonstrated in the reduction of serum alkaline phosphatase (SAP). The extended observation period included participants of the core study who responded to treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Calcium; Calcium, Dietary; Diphosphonates; Ergocalciferols; Etidronic Acid; Risedronate Sodium; Risedronic Acid; Vitamin D; Vitamins; Zoledronic Acid

Criteria

Inclusion Criteria:

• 30 years or older

• Serum alkaline phosphatase (SAP) 2 times upper limit normal (ULN)

• Confirmed diagnosis of Paget's disease of the bone (by x-ray, magnetic resonance imaging, computerized tomography, radioisotope imaging, etc.).

• 90 days washout calcitonin

• 180 day washout bisphosphonate

Exclusion Criteria:

• Allergic reaction to bisphosphonates

• History of upper gastrointestinal disorders

• History of iritis, uveitis

• Calculated creatinine clearance < 30 ml/min at baseline

• Evidence of vitamin D deficiency

Other protocol-defined inclusion/exclusion criteria applied.